Tumour necrosis factor -308 and -238 promoter polymorphisms are predictors of a null virological response in the treatment of Brazilian hepatitis C patients

Detalhes bibliográficos
Autor(a) principal: Grandi, Tarciana
Data de Publicação: 2014
Outros Autores: Silva, Cláudia Maria Dornelles da, Amaral, Karine Medeiros, Picon, Paulo Dornelles, Costi, Cintia, Fré, Nicole Nascimento da, Fiegenbaum, Marilu, Gregianini, Tatiana Schäffer, Niel, Christian, Rossetti, Maria Lucia Rosa
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/10830
Resumo: Fundação Estadual de Produção e Pesquisa em Saúde. Centro de Desenvolvimento Científico e Tecnológico. Porto Alegre, RS, Brasil / Universidade Federal do Rio Grande do Sul. Programa de Pós-Graduação em Biologia Celular e Molecular. Porto Alegre, RS, Brasil.
id CRUZ_a7d147a2fdee9467303a7aac758760e9
oai_identifier_str oai:www.arca.fiocruz.br:icict/10830
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Grandi, TarcianaSilva, Cláudia Maria Dornelles daAmaral, Karine MedeirosPicon, Paulo DornellesCosti, CintiaFré, Nicole Nascimento daFiegenbaum, MariluGregianini, Tatiana SchäfferNiel, ChristianRossetti, Maria Lucia Rosa2015-06-12T13:57:54Z2015-06-12T13:57:54Z2014GRANDI, Tarciana et al. Tumour necrosis factor -308 and -238 promoter polymorphisms are predictors of a null virological response in the treatment of Brazilian hepatitis C patients. Mem Inst Oswaldo Cruz, v.109, n.3, p.345-351, May 2014.1678-8060https://www.arca.fiocruz.br/handle/icict/1083010.1590/0074-0276130372engFundação Oswaldo CruzPolimorfismoTNFPolymorphismsHCVVirological respondeBrazilHepacivirusLinfotoxina-alfaReceptores do Fator de Necrose TumoralTumour necrosis factor -308 and -238 promoter polymorphisms are predictors of a null virological response in the treatment of Brazilian hepatitis C patientsinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleFundação Estadual de Produção e Pesquisa em Saúde. Centro de Desenvolvimento Científico e Tecnológico. Porto Alegre, RS, Brasil / Universidade Federal do Rio Grande do Sul. Programa de Pós-Graduação em Biologia Celular e Molecular. Porto Alegre, RS, Brasil.Fundação Estadual de Produção e Pesquisa em Saúde. Centro de Desenvolvimento Científico e Tecnológico. Porto Alegre, RS, Brasil / Universidade Federal do Rio Grande do Sul. Programa de Pós-Graduação em Biologia Celular e Molecular. Porto Alegre, RS, Brasil / Universidade Luterana do Brasil. Programa de Pós-Graduação em Genética e Toxicologia Aplicada. Canoas, RS, Brasil.Centro de Aplicação e Monitorização de Medicamentos Injetáveis. Porto Alegre, RS, Brasil.Centro de Aplicação e Monitorização de Medicamentos Injetáveis. Porto Alegre, RS, Brasil.Fundação Estadual de Produção e Pesquisa em Saúde. Centro de Desenvolvimento Científico e Tecnológico. Porto Alegre, RS, Brasil .Fundação Estadual de Produção e Pesquisa em Saúde. Centro de Desenvolvimento Científico e Tecnológico. Porto Alegre, RS, BrasilUniversidade Federal de Ciências da Saúde. Programa de Pós-Graduação em Patologia. Programa de Pós-Graduação em Ciências da Saúde. Porto Alegre, RS, Brasil / Centro Universitário Metodista. Instituto Porto Alegre. Programa de Pós-Graduação em Biociências e Reabilitação. Porto Alegre, RS, Brasil.Fundação Estadual de Produção e Pesquisa em Saúde. Laboratório de Vírus Respiratórios. Porto Alegre, RS, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Virologia Molecular. Rio de Janeiro, RJ, Brasil.Fundação Estadual de Produção e Pesquisa em Saúde. Centro de Desenvolvimento Científico e Tecnológico. Porto Alegre, RS, Brasil / Universidade Federal do Rio Grande do Sul. Programa de Pós-Graduação em Biologia Celular e Molecular. Porto Alegre, RS, Brasil / Universidade Luterana do Brasil. Programa de Pós-Graduação em Genética e Toxicologia Aplicada. Canoas, RS, Brasil.Certain host single nucleotide polymorphisms (SNPs) affect the likelihood of a sustained virological response (SVR) to treatment in subjects infected with hepatitis C virus (HCV). SNPs in the promoters of interleukin (IL)-10 (-1082 A/G, rs1800896), myxovirus resistance protein 1 (-123 C/A, rs17000900 and -88 G/T, rs2071430) and tumour necrosis factor (TNF) (-308 G/A, rs1800629 and -238 G/A, rs361525) genes and the outcome of PEGylated α-interferon plus ribavirin therapy were investigated. This analysis was performed in 114 Brazilian, HCV genotype 1-infected patients who had a SVR and in 85 non-responders and 64 relapsers. A significantly increased risk of having a null virological response was observed in patients carrying at least one A allele at positions -308 [odds ratios (OR) = 2.58, 95% confidence intervals (CI) = 1.44-4.63, p = 0.001] or -238 (OR = 7.33, 95% CI = 3.59-14.93, p < 0.001) in the TNF promoter. The risk of relapsing was also elevated (-308: OR = 2.87, 95% CI = 1.51-5.44, p = 0.001; -238: OR = 4.20, 95% CI = 1.93-9.10, p < 0.001). Multiple logistic regression of TNF diplotypes showed that patients with at least two copies of the A allele had an even higher risk of having a null virological response (OR = 16.43, 95% CI = 5.70-47.34, p < 0.001) or relapsing (OR = 6.71, 95% CI = 2.18-20.66, p = 0.001). No statistically significant association was found between the other SNPs under study and anti-HCV therapy response.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txttext/plain1914https://www.arca.fiocruz.br/bitstream/icict/10830/1/license.txt7d48279ffeed55da8dfe2f8e81f3b81fMD51ORIGINALchristian_nieletal_IOC_2014.pdfapplication/pdf377925https://www.arca.fiocruz.br/bitstream/icict/10830/2/christian_nieletal_IOC_2014.pdfe94801a7263d106f56fda1c4aee0ccdcMD52TEXTchristian_nieletal_IOC_2014.pdf.txtchristian_nieletal_IOC_2014.pdf.txtExtracted texttext/plain36990https://www.arca.fiocruz.br/bitstream/icict/10830/3/christian_nieletal_IOC_2014.pdf.txt1a4c4e32ce98fff2da06fb5c78fed3bbMD53icict/108302022-06-24 12:18:55.811oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352022-06-24T15:18:55Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv Tumour necrosis factor -308 and -238 promoter polymorphisms are predictors of a null virological response in the treatment of Brazilian hepatitis C patients
title Tumour necrosis factor -308 and -238 promoter polymorphisms are predictors of a null virological response in the treatment of Brazilian hepatitis C patients
spellingShingle Tumour necrosis factor -308 and -238 promoter polymorphisms are predictors of a null virological response in the treatment of Brazilian hepatitis C patients
Grandi, Tarciana
Polimorfismo
TNF
Polymorphisms
HCV
Virological responde
Brazil
Hepacivirus
Linfotoxina-alfa
Receptores do Fator de Necrose Tumoral
title_short Tumour necrosis factor -308 and -238 promoter polymorphisms are predictors of a null virological response in the treatment of Brazilian hepatitis C patients
title_full Tumour necrosis factor -308 and -238 promoter polymorphisms are predictors of a null virological response in the treatment of Brazilian hepatitis C patients
title_fullStr Tumour necrosis factor -308 and -238 promoter polymorphisms are predictors of a null virological response in the treatment of Brazilian hepatitis C patients
title_full_unstemmed Tumour necrosis factor -308 and -238 promoter polymorphisms are predictors of a null virological response in the treatment of Brazilian hepatitis C patients
title_sort Tumour necrosis factor -308 and -238 promoter polymorphisms are predictors of a null virological response in the treatment of Brazilian hepatitis C patients
author Grandi, Tarciana
author_facet Grandi, Tarciana
Silva, Cláudia Maria Dornelles da
Amaral, Karine Medeiros
Picon, Paulo Dornelles
Costi, Cintia
Fré, Nicole Nascimento da
Fiegenbaum, Marilu
Gregianini, Tatiana Schäffer
Niel, Christian
Rossetti, Maria Lucia Rosa
author_role author
author2 Silva, Cláudia Maria Dornelles da
Amaral, Karine Medeiros
Picon, Paulo Dornelles
Costi, Cintia
Fré, Nicole Nascimento da
Fiegenbaum, Marilu
Gregianini, Tatiana Schäffer
Niel, Christian
Rossetti, Maria Lucia Rosa
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Grandi, Tarciana
Silva, Cláudia Maria Dornelles da
Amaral, Karine Medeiros
Picon, Paulo Dornelles
Costi, Cintia
Fré, Nicole Nascimento da
Fiegenbaum, Marilu
Gregianini, Tatiana Schäffer
Niel, Christian
Rossetti, Maria Lucia Rosa
dc.subject.other.pt_BR.fl_str_mv Polimorfismo
topic Polimorfismo
TNF
Polymorphisms
HCV
Virological responde
Brazil
Hepacivirus
Linfotoxina-alfa
Receptores do Fator de Necrose Tumoral
dc.subject.en.pt_BR.fl_str_mv TNF
Polymorphisms
HCV
Virological responde
Brazil
dc.subject.decs.pt_BR.fl_str_mv Hepacivirus
Linfotoxina-alfa
Receptores do Fator de Necrose Tumoral
description Fundação Estadual de Produção e Pesquisa em Saúde. Centro de Desenvolvimento Científico e Tecnológico. Porto Alegre, RS, Brasil / Universidade Federal do Rio Grande do Sul. Programa de Pós-Graduação em Biologia Celular e Molecular. Porto Alegre, RS, Brasil.
publishDate 2014
dc.date.issued.fl_str_mv 2014
dc.date.accessioned.fl_str_mv 2015-06-12T13:57:54Z
dc.date.available.fl_str_mv 2015-06-12T13:57:54Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv GRANDI, Tarciana et al. Tumour necrosis factor -308 and -238 promoter polymorphisms are predictors of a null virological response in the treatment of Brazilian hepatitis C patients. Mem Inst Oswaldo Cruz, v.109, n.3, p.345-351, May 2014.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/10830
dc.identifier.issn.pt_BR.fl_str_mv 1678-8060
dc.identifier.doi.pt_BR.fl_str_mv 10.1590/0074-0276130372
identifier_str_mv GRANDI, Tarciana et al. Tumour necrosis factor -308 and -238 promoter polymorphisms are predictors of a null virological response in the treatment of Brazilian hepatitis C patients. Mem Inst Oswaldo Cruz, v.109, n.3, p.345-351, May 2014.
1678-8060
10.1590/0074-0276130372
url https://www.arca.fiocruz.br/handle/icict/10830
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Fundação Oswaldo Cruz
publisher.none.fl_str_mv Fundação Oswaldo Cruz
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/10830/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/10830/2/christian_nieletal_IOC_2014.pdf
https://www.arca.fiocruz.br/bitstream/icict/10830/3/christian_nieletal_IOC_2014.pdf.txt
bitstream.checksum.fl_str_mv 7d48279ffeed55da8dfe2f8e81f3b81f
e94801a7263d106f56fda1c4aee0ccdc
1a4c4e32ce98fff2da06fb5c78fed3bb
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1813009240138186752

Registros relacionados